Aminopyrimidine/Pyrazine CTPS1 Inhibitors for Isozyme Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for targeting cytidine triphosphate synthase 1 (CTPS1) lack selective inhibitors with high potency, good cellular permeability, high free fraction, desirable pharmacodynamic and pharmacokinetic parameters, and distinct metabolites, which are essential for effectively inhibiting immune and cancer cell populations without significant side effects.
Innovation Solution
Development of novel aminopyrimidine/pyrazine derivatives that selectively inhibit CTPS1 over CTPS2, demonstrating IC50 values of 1 uM or lower and selectivity ratios of 2-30 fold, suitable for pharmaceutical use as inhibitors of CTPS1 in various diseases and disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current CTPS1 inhibitors are developed, then inhibition potency may be improved, but selectivity over CTPS2 and cellular permeability are insufficient
Solution Approach 1:
The patent divides the CTPS enzyme into two distinct isozymes (CTPS1 and CTPS2) and develops inhibitors that specifically target CTPS1. The compounds are designed to exploit structural differences between the isozymes, achieving selective inhibition of CTPS1 while sparing CTPS2, thereby resolving the contradiction between potency and selectivity.
Solution Approach 2:
The patent introduces specific chemical modifications at particular positions of the pyrimidine/pyrazine core structure (such as substituents at positions 2, 4, 6 and specific ring fusion patterns) to create local structural features that preferentially bind to CTPS1. This localized structural optimization enables both high potency and selectivity simultaneously.
2Productivity
If non-selective CTPS inhibitors are used, then broad immunosuppression is achieved, but toxicity and side effects increase
Solution Approach 1:
The patent extracts and targets specifically the CTPS1 enzyme pathway that is critical for activated lymphocyte proliferation, while leaving the CTPS2 pathway intact. This selective targeting achieves the desired immunosuppression effect on pathogenic immune cells while preserving normal physiological functions that depend on CTPS2, thereby reducing toxicity and side effects.
Solution Approach 2:
The patent uses CTPS1 as a selective intermediary target that mediates the immunosuppressive effect. By inhibiting CTPS1 specifically in activated immune cells, the compounds achieve therapeutic effects through this intermediary pathway while avoiding direct toxic effects on other systems, thus resolving the contradiction between efficacy and safety.
3Reliability
If existing CTPS1 inhibitors are developed, then lymphocyte proliferation inhibition is improved, but pharmacokinetic parameters and metabolic profile are inadequate
Solution Approach 1:
The patent systematically varies key chemical parameters including the core heterocyclic structure (pyrimidine vs pyrazine), substituent types and positions, and molecular weight to optimize both biological activity and pharmacokinetic properties. This parameter optimization ensures that the compounds achieve effective lymphocyte proliferation inhibition while maintaining desirable absorption, distribution, metabolism, and excretion characteristics.
Data Source
AI summary
Compounds of formula (I):and related aspects.